Video in which Prof.  Mohamad Mohty, Sorbonne hospital St Antoine (Paris) explains the significance of lenalidomide in treating patients with multiple myeloma.
In the video he distinguishes between lenalidomide-sensitive and lenalidomide refractory patients. 

Pharmaceutical class : Proteasome Inhibitors (PI)
Active compound : Ixazomib

NINLARO, in combination with lenalidomide and dexamethasone, is the 1st and only reimbursed Oral PI-triplet combination.

NRd is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Available dosages & packagings :

• 3 x 4mg
• 3 x 3 mg
• 3 x 2.3mg